Table 1 Baseline NAR characteristics of the patients.

From: Predicting outcomes for locally advanced rectal cancer treated with neoadjuvant chemoradiation with CT-based radiomics

 

No. of patients

NAR > 16

NAR < 8

No (%)

OR (95% CI)

P-value

No (%)

OR (95% CI)

P-value

Total no. of patients

62.6 (11.7)

191

74

–

–

36

–

–

Clinical diagnosis

Age, years

191

62.6 (11.7)

1.01 (0.98 to 1.04)

0.477

58.8 (11.5)

0.97 (0.93 to 1.00)

0.046*,†

cT stage

 T2

11

3 (4.05)

Ref.

Ref.

3 (8.33)

Ref.

Ref

 T3

141

58 (78.4)

1.80 (0.49 to 8.97)

0.393

29 (80.6)

0.67 (0.18 to 3.40)

0.597

 T4

39

13 (17.6)

1.30 (0.30 to 7.09)

0.737

4 (11.1)

0.31 (0.05 to 1.97)

0.203

cN stage

 N0

43

8 (10.8)

Ref.

Ref.

11 (30.6)

Ref.

Ref.

 N1

110

47 (63.5)

3.20 (1.41 to 8.08)

0.005*,†

21 (58.3)

0.69 (0.30 to 1.63)

0.384

 N2

38

19 (25.7)

4.25 (1.60 to 12.2)

0.003*,†

4 (11.1)

0.35 (0.09 to 1.17)

0.091*

CEA at diagnosis

191

21.6 (41.6)

1.00 (1.00 to 1.00)

0.740

4.23 (5.76)

0.92 (0.86 to 0.99)

0.019*,†

Treatments

Adjuvant chemotherapy

 Yes

144

58 (78.4)

Ref.

Ref.

29 (80.6)

Ref.

Ref.

 No

47

16 (21.6)

0.77 (0.38 to 1.52)

0.455

7 (19.4)

0.71 (0.26 to 1.67)

0.441

Surgical margin

 Close

8

2 (2.70)

0.55 (0.07 to 2.58)

0.470

2 (5.56)

1.31 (0.17 to 6.22)

0.763

 Positive

26

11 (14.9)

1.16 (0.48 to 2.69)

0.738

1 (2.78)

0.17 (0.01 to 0.86)

0.028*,†

 Clear

157

61 (82.4)

Ref.

Ref.

33 (91.7)

Ref.

Ref.

 Time RT to surgery, days

191

69.1 (26.0)

1.00 (0.99 to 1.00)

0.572

73.9 (61.3)

1.00 (0.99 to 1.01)

0.820

Pathology

pT stage

 T0

27

1 (1.35)

Ref.

Ref.

25 (69.4)

Ref.

Ref.

 T1

11

0 (0.00)

2.31 (0.06 to 95.3)

0.615

9 (25.0)

0.35 (0.03 to 3.77)

0.361

 T2

34

11 (14.9)

10.8 (1.84 to 279)

0.005*,†

2 (5.56)

0.01 (0.00 to 0.04)

 < 0.001*,†

 T3

99

48 (64.9)

20.8 (4.16 to 506)

 < 0.001*,†

0 (0.00)

0.00 (0.00 to 0.01)

 < 0.001*,†

 T4

19

14 (18.9)

48.3 (7.53 to 1330)

 < 0.001*,†

0 (0.00)

0.01 (0.00 to 0.05)

 < 0.001*,†

pN stage

 N0

116

2 (2.70)

Ref.

Ref.

35 (97.2)

Ref.

Ref.

 N1

61

58 (78.4)

853 (177 to 7709)

 < 0.001*,†

1 (2.78)

0.05 (0.00 to 0.22)

 < 0.001*,†

 N2

13

13 (18.9)

533 (69.6 to 15,143)

 < 0.001*,†

0 (0.00)

0.19 (0.01 to 1.03)

0.055*

  1. *P < 0.1, †P < 0.05.
  2. The data are shown as the number (percentage) or median (interquartile range).
  3. CEA carcinoembryonic antigen.
Back to article page